During Q4, the company billed 11,789 tissue-based units and 12,036 liquid-based units, representing growth of 50% and 10%, respectively.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks